# A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

> **NCT04202705** · PHASE1 · COMPLETED · sponsor: **Byondis B.V.** · enrollment: 31 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** SYD1875

## Key facts

- **NCT ID:** NCT04202705
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-28
- **Primary completion:** 2022-06-22
- **Final completion:** 2023-01-26
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04202705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04202705, "A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04202705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*